Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Current Leases (2019 - 2025)

Corcept Therapeutics' Current Leases history spans 7 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Current Leases rose 30.76% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 30.76%, while the annual FY2025 figure was $1.1 million, 30.76% up from the prior year.
  • Current Leases for Q4 2025 was $1.1 million at Corcept Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.3 million in Q1 2022 and bottomed at $44000.0 in Q2 2024.
  • The 5-year median for Current Leases is $1.0 million (2025), against an average of $967000.0.
  • The largest annual shift saw Current Leases tumbled 86.88% in 2023 before it skyrocketed 2211.36% in 2025.
  • A 5-year view of Current Leases shows it stood at $526000.0 in 2021, then soared by 117.3% to $1.1 million in 2022, then tumbled by 86.79% to $151000.0 in 2023, then surged by 449.01% to $829000.0 in 2024, then surged by 30.76% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Current Leases are $1.1 million (Q4 2025), $1.0 million (Q3 2025), and $1.0 million (Q2 2025).